TABLE OF CONTENTS
FEATURES
Determining Whether a Substance is Legal to Compound Under Section 503a of the FDCA
Filling the Gaps on the Institute for Safe Medication Practices' Do Not Crush List for Immediate-release Products
Compounding Pearls - Wound Care: Drugs and Formulations for Dermal Healing, Part 3 - The Roles of Nitric Oxide, Sildenafil, and Naltrexone
Realities of Pharmaceutical Compounding in the Republic of Uzbekistan
It's Time for a New Philosophy - For years the FDA's approach to compounding has been all vinegar. How about some honey for a (strategic) change?
DEPARTMENTS
Prescription: Permissible Exposure Limits and United States Pharmacopeia Chapter <800>
Calculations
APPLIED COMPOUNDING
How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 2
Excipients Used in Nonsterile Compounding, Part 11: Drug Tastes: Innate, Induced, and Improved
Basics of Sterile Compounding - Intravenous Admixture Preparation, Part 11: Particulate Issues -Silicone Oil in Vials, Cartridges, and Syringes
PEER REVIEW
Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application
Stability of Diazepam Enema Extemporaneous Formulation in Manzoni Base
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
FORMULATIONS
Atropine Sulfate 0.1 mg/mL in SyrSpend SF PH4 Oral Suspension
Cilaprazil 1 mg/mL in OraBlend Suspension
Clonidine 0.01 mg/mL in OraBlend
Dapsone 2 mg/mL in Oral Mix or Oral Mix SF Suspension
Dexamethasone 1 mg/mL in Oral Mix and Oral Mix SF
Haloperidol 0.5 mg/mL in SyrSpend SF PH4
Imipramine Hydrochloride 5 mg/mL in SyrSpend SF PH4
Mycophenolate Mofetil 50 mg/mL in Ora-Plus: Cherry Syrup Suspension
Sorafenib 20 mg/mL in Ora-Sweet and Ora-Plus Suspension
Spironolactone 2 mg/mL and 2.5 mg/mL in SyrSpend SF PH4
|